41 related articles for article (PubMed ID: 10698504)
1. Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein.
Chen C; Agnès F; Gélinas C
Mol Cell Biol; 1999 Jan; 19(1):307-16. PubMed ID: 9858554
[TBL] [Abstract][Full Text] [Related]
2. AP-1 factors play an important role in transformation induced by the v-rel oncogene.
Kralova J; Liss AS; Bargmann W; Bose HR
Mol Cell Biol; 1998 May; 18(5):2997-3009. PubMed ID: 9566919
[TBL] [Abstract][Full Text] [Related]
3. The amino acid region from 448-517 of CAMTA3 transcription factor containing a part of the TIG domain represses the N-terminal repression module function.
Abdel-Hameed AAE; Prasad KVSK; Reddy ASN
Physiol Mol Biol Plants; 2023 Dec; 29(12):1813-1824. PubMed ID: 38222273
[TBL] [Abstract][Full Text] [Related]
4. Ligandability assessment of the C-terminal Rel-homology domain of NFAT1.
Böttcher J; Fuchs JE; Mayer M; Kahmann J; Zak KM; Wunberg T; Woehrle S; Kessler D
Arch Pharm (Weinheim); 2024 Feb; ():e2300649. PubMed ID: 38396281
[TBL] [Abstract][Full Text] [Related]
5. NFκB function and regulation in cutaneous T-cell lymphoma.
Chang TP; Vancurova I
Am J Cancer Res; 2013 Nov; 3(5):433-45. PubMed ID: 24224122
[TBL] [Abstract][Full Text] [Related]
6. Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL.
Leeman JR; Weniger MA; Barth TF; Gilmore TD
Oncogene; 2008 Dec; 27(53):6770-81. PubMed ID: 18695674
[TBL] [Abstract][Full Text] [Related]
7. Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression.
Wang Z; Zhang B; Yang L; Ding J; Ding HF
J Biol Chem; 2008 Apr; 283(16):10698-706. PubMed ID: 18281283
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis.
Zhang B; Wang Z; Li T; Tsitsikov EN; Ding HF
Blood; 2007 Jul; 110(2):743-51. PubMed ID: 17405906
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.
Liss AS; Bose HR
J Virol; 2002 May; 76(10):4928-39. PubMed ID: 11967310
[TBL] [Abstract][Full Text] [Related]
10. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
Gilmore TD
Oncogene; 1999 Nov; 18(49):6925-37. PubMed ID: 10602467
[TBL] [Abstract][Full Text] [Related]
11. Aberrant rel/nfkb genes and activity in human cancer.
Rayet B; Gélinas C
Oncogene; 1999 Nov; 18(49):6938-47. PubMed ID: 10602468
[TBL] [Abstract][Full Text] [Related]
12. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
[TBL] [Abstract][Full Text] [Related]
13. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
Epinat JC; Dvorin EL; Gilmore TD
Oncogene; 2000 Jun; 19(28):3131-7. PubMed ID: 10918567
[TBL] [Abstract][Full Text] [Related]
14. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
15. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
Sarkar S; Gilmore TD
Oncogene; 1993 Aug; 8(8):2245-52. PubMed ID: 8336947
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
